How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation.
Shigeo FujiMichael ByrneArnon NaglerMohamad MohtyBipin N SavaniPublished in: Bone marrow transplantation (2021)
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with a hematologic disease. Although the clinical outcomes after allo-HCT have significantly improved during the last few decades, graft-versus-host disease (GVHD) is still a major cause of post-HCT morbidity and mortality. Systemic glucocorticoids (GC) remain an integral part of treatment in patients with GVHD including both acute and chronic GVHD. Although it is well-known that usage of systemic GC is associated with various side effects, the short- and long-term effects of GCs in the HCT setting are not well-characterized due to limited published data. In order to clarify this issue, we summarize the information on side effects associated with GCs, focusing specifically on the sequelae of these agents in the early post-HCT period. In instances where limited data are available, we included data from other fields such as autoimmune diseases, given the potential parallels between autoimmune conditions and GVHD.
Keyphrases
- cell cycle arrest
- electronic health record
- allogeneic hematopoietic stem cell transplantation
- stem cell transplantation
- drug induced
- big data
- multiple sclerosis
- randomized controlled trial
- intensive care unit
- machine learning
- cell death
- low dose
- risk assessment
- acute myeloid leukemia
- combination therapy
- high dose
- mass spectrometry
- acute lymphoblastic leukemia
- artificial intelligence
- respiratory failure
- extracorporeal membrane oxygenation
- high resolution
- replacement therapy
- liquid chromatography